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まとめ
界面活性弗jを加えた仔牛血清 albumin と MMCの
混合液を加熱讃持することにより， 45土 8tmの直径を
有する小球捧 (microsphere) を作製し，その invivo， 
in vItro における MMCの徐放性を確め，次いで蕗床
例iこ投与し市販 M羽C では得られない抗腫療効果を認
めた。
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As demonstrated by many investigators1・汽 
vertical transmission of hepatitis B virus (HBV) 
from carrier women to their 0宜springappears 
to be a principal source of hepatitis B surface 
antigen (HBsAg) carriers in Japan. HBsAg car-
riers may potentially run the risk of developing 
chronic active hepatitis，liver cirrhosis or hepa-
toma心 Atpresent，we have no means of re-
moving HBV from carriers successfully even with 
interferon5) or adenine arabinosideめ. Accordingly-
it is quite impo主tantto prevent the development 
of carrier state in the infants born from the carrier 
women. 
Materials and菰 ethods 
Hepatitis B vaccine (HB vaccine) was administ-
ered to 43 volunteers，7 males and 36 females， 
who worked for Chiba University Hospital. 
Their Ages varied from 21 to 59 years old. 
All of them were free from HBsAg，hepatitis B 
surface antibody (HBsAb) and hepatitis B core 
antibody (HBcAb). With liver function tests， 
they stayed al within normal limits prior to the 
first HB vaccInation. During the period from 
April 1981 to April 1983，thirty two infants born 
from the carrier women with hepatitis B e antigen 
(HBeAg) have received hepatitis B immunoglobu-
lin (HBIG) and HB vaccine to prevent the de-
velopment of HBV carrier state. Their umらili-
cal cord sera were con五rmed to be negative 
for HBsAg and HBsAb by reverse passive he-
magglutination (R・PHA)and passive hemagglu・ 
tination (PHA)，respectively. AII newborns appa-
rent1y seemed normal at birth. 
Used HBIG was donated by Green Cross Ltd. 
(Lot. 107GS，Osaka) and The Chemo・sero-thera-
peutic Research Institute (Lot. 12，14，16 and 
17，Kumamoto). These products were pur通話
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from human HBsAb-positive sera and lyophilized 
for storage. They carried basically over 32000 
HBsAb-titers by PHA. 日 Bvaccination was per-
formed with 2 kinds of HB vaccine 0宜 eredby 
Kitasato lnstitute (Lot. 001GD and TV-1， 
Tokyo) and The Chemo・ sero-therapeuticResear-
ch lnstitute (Lot. KB・1). They were puri五 ed 
from human HBsAg-and HBeAb-positive as well 
as deoxyribonucleic acid (DNA) 'pv1ymerase actI-
vity-negative sera. These products contained 40 
pg/ml of HBsAg as protein and 200μg/ml of 
Al (OH)s as an adjuvant， and were exh~，u成ively 
free from Dane particles. ln addition， they were 
inactivated at 600 C for 10 hours and then with 
formalin diluted 1:2000 at 370C for 96 hours. 
Twenty one of the 43 volunteers were vaccina-
ted with 40μg HBsAg and the remainders， with 
20 pg HBsAg. An additional vaccination was 
peτformed within one monthafter the五 rstvaccina-
tion. ln the latter， the third vaccination was car-
ried out around 9-10 months after the五 rstvacci-
nation. All the 32 infants except one received 
the五 rst HBIG within 24 hours after birth. 
Thereafter， they received combined passive and 
active immunIzation with 1 ml of HBIG and 4 pg 
of HB vaccine intramascularly and subcutane-
ously， respectively， according to the protocol (Ta-
ble 1). These 43 volunteers and 32 infants under-
went liver function checks and testing for HBsAg， 
HBsAb and HBcAb at approximately one and 2 
weeks， and every one month after the immuniza-
tion. Besides， these 32 infants underwent urina-
lysis occasionally. 
Testing for HBsAg was carried out by R-PHA 
(Yamanouchi Ltd.， Osaka)， enzyme immu∞ assay 
(EIA: Behringwerke AG， Marburg/FRG) and 
radioimmunoassay (RIA: Abbott， Chicago/U. S. 
Aふ HBsAb was determined by PHA (Eisai 
Ltd.， Tokyo) and RIA (Abbott). HBeAg and 
hepatitis B e antibody (HBeAb)were measured 
by RIA (Abbott) and EIA (Behringwerke AG). 
HBcAb was determined by RIA (Abbott). 
Results 
The cumulative detection rates of 1王 BsAbin 
the 43 volunteers vaccinated with 20μg (de五 ned 
group 20) and 40μg (de五 nedgroup 40) of HBs-
Ag are summarized in Table 2 by periods after 
Table 1. Protocol of combined passive and active Immunization 
No. of cases HBIG administration HB vaccination 
Group A 
Group B 
Group C 
Group D 
G主 oup E 
8 
5 
13 
1 
5 
0， 4， 8， 12M 
0， 3ラ 6， 9， 12M 
0， 3M 
3， 6， 10， 13~νI 
0， 3M 
12， 13M and additional vaccination， ifnecessary 
12， 13五1: and additional vaccination， ifnecessary 
4， 51¥在 and additional vaccination， ifnecessary 
14， 15M 
2， 3M and additional vaccination， ifnecessary 
M: Months 
Table 2. Cumulative detection rates of HBsAb after HB vaccination 
HBsAg Detection 
dose methods 2W 1M 2M 31¥在 4M 5M 6主 7乱1: 8M 9M 10M 11M 121¥在 
20μg R-PHA o 0 4 4 9 11 11 11 11 12キ 21 21 
(n :22) (0 )(0 )(18.1) (18.1) (40.9) (50.0) (50.0) (50.0) (50.0) (54.5) (95.5) (95.5) 
RIA o 1 7 12 14 15 16 16 16 17 
(0 )( 4.5) (31. 8) (54.5) (63.6) (68.1) (72.7) (72.7) (72.7)77.3) 
4(0aμ:g21) 
R-PHA 1 1 3 12 12 13 13 13 13 13 14 
( 4.8)( 4.8)(14.3)(57.1)(57.1)(61.9)(61.9)(61.9)(61.9)(66.7) (66.7)一 
14 
(66.7) 
RIA 15 16 16 16 16 16 16 16 
(71.4)(76.2)(76.2)(76.2)(76.2)(76.2)(76.2)一 (76.2)
ヰ: The third booster vaccination was added. W: Weeks M :蛙 onths 
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vaccination. 1n group 40，HBsAb was長rstdetec-
ted in a female within 2 weeks after vaccination. 
The detection rates of HBsAる byR-PHA incr-
eased slowly in the period from 2 to 8 weeks， 
and rapidly during the period仕om2 to 3 Inonths， 
attaining approximately 57%. The五naldetec-
tion rates amounted to 66.7% by R-PHA and 
76.2% by R1A. 1n group 20，the detection rate 
of HBsAb revealed a more slowly increasing cu-
rve by R・PHA，attaining 54.5%. However，wi-
thin 4 months the detection rates by R1A were 
founed to be as high as those in group 40. 1n 
group 20，the marked increase of HBsAb detection 
rates was found after the third vaccination. Of 
22 volunteers，twenty one (95.5%) represented 
HBs-Ab-positive by R-PHA one month after the 
third vaccination. 
While ~6 of 36 females (72.2%) developed HBs 
Ab-positive by the second vaccination，al1seven 
males，who were. younger than 40 years old， 
acquired immunity from HBV. Twenty three of 
27 females (85.2%) who were younger than 40 
years old became HBsAb-positive by the second 
vaccination. On the other hand，only three of 9 
females (33.3%) who were older than 40 years old 
developed HBsAb-positive. 
No uncomfortable symptoms such as pyrexia， 
arthrodynia and anaphylactic shock were compla-
ined of. 
As summarjzed in Table 3，長 fteenof the 32 
infants born from HBeAg-positive carrier women 
had acquired immunity from HBV by combined 
passive and active immunization，while mere 2 of 
the infants (6.3弘)developed carrier state. These 
2 carrier infants were treated according to the 
protocol of group A. On the other hand，no 
carriers had taken place in the other groups. 
1n group A，B and D where active immuniza-
tion was carried out beyond 12 months after birth， 
eight of 14 infants (57.1%) represented persistent 
HBsAb-positive. Similarly 7 of 13 infants (53.8%) 
had acquired immunity from HBV in group C 
where the五rstactive immunization was performed 
at the age of 4 months. 1n group E，the out-
come of 5 infants remains stil undetermined. 
To elucidate possible e宜ectsof HB1G on the 
liver function，serum glutamic pyruvic transami-
nase (S-GTP) was repeatedly measured for one 
year in 20 infants who received託 B1Gand 18 con・ 
trol ones born from HBeAg-positive carrier wo・ 
rrien and followed up without any medication. 
1n the 18 control infants，S-GPT values ranged 
from 18 to 331 mu/ml (mean value: 69 mu/ml)， 
while SGPTvalues varied from 8 to 113 mu/ml 胃 
(mean value: 32 mu/ml) in the 20 ones who 
received HB1G. Besides，no side e旺ectsof HB1G 
and HB vaccine had been appreciated both locally 
and systemically. Furthermore，HBcAb was not 
detected in the 43 volunteers with HB vaccination. 
Discussion 
Clinical utility of HB vaccine in preventing 
Table 3. Outcome of 32 infants with combined passive and active immunization 
Groups No of cases Undetermined Carrier state Persistent HBsAb 
Group A 
Group B 
Group C 
Group D 
Group E 
8 
5 
13 
l 
5 
1 
3 
6。
5 
2。。。。
5 
2 
7 
1。 
Total 32 15 2( 6.3%) 15(46.9%)* 
Control 78 6** 57(73.1%) 15(19.2%) 
Control : 78 infants born to HBeAg-positive carrier women (without immun-
ization) 
* : Percentage (%) 
料:Six infants stayed free from HBV infection at age 24 months. 
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HBV horizontal infection was伝 stdescribed by 
Krugman et al.7). To prevent HBV vertical trans-
8) applied HBIG to 3 neo1. Kohler et a，mission ・ 
nates successfully. For the last decade， passive 
and/or active immunIzation with HBIG and豆 B 
vaccine has been theoretically accepted as one of 
rational means for preventing HBV infection. 
However， practical details of these therapeutic 
methods are sti1l under investigation. 
To elucidate fundamental e伍 cacyand vaccina-
tion method of HB vaccine， two di百 erentdoses 
of HBsAg， i.e. 20 and 40μg， were applied to 
43 volunteers. Their immune responses were qui-
cker in group 40 than in the other， supporting 
there，9). However1. the results of Szmuness et a 
were no signi五 cantdi吉 erencesin the final rate 
of HBsAb occurrence between the two groups， 
suggesting su昆 ciencyof 20μg HBsAg for raising 
HBsAb in adult cases. This study also demonst-
rated that the長 rstand second booster vaccina-
tion could immunIz e approximately 80% of cases 
successfully in accord with the report of Yano et 
the third booster vaccination re-，Besides) . 101. a 
vealed signi五 cant1yhigh e岳 cacy(p < 0.005) in rais-
ing HBsAb in the remaining non-responders， at-
taining 96% in rate of HBsAb occurrence. 
W ith their immune responses to HB vaccine， 
there were no marked di茸 erencesby sex. On 
the other hand， the volunteers under 40 years 
old achieved signi五 cantlyhigher acquistion of HBs-
Ab (p<0.005)， as compared with that of the 
volunteers over 40 years old. 
lD have already demonstrated that ，21. Inaba et a
73.1% of the 78 infants born from HBeAg-po・ 
sitive carrier women developed carrier state within 
4 months postnatally， 19.2弘 acquiredpersistent 
HBsAb during the period of 2-8 months and 
mere 7.7% remained free from HBV infection 
for 24 months (control in Table 3). On the 
other hand， only 6.3% of the 32 infants who were 
born from HBeAg-positive carrier women and 
received combined passive and active immunization 
developed carrier state， indicating remarkable e缶・ 
cacy of HBIG in the prevention of infantile 
development of carrier state. These two carrier 
infants in group A received HBIG every 4 months， 
while no children. had developed carrier state in 
the other groups where HBIG was administered 
every 3 months. These data suggest that 4 mo・ 
nth-interval of HBIG administration may be too 
long and 3 month-interval、 adequate length of 
period to mainatin circulating HBIG in refering 
to the decreasing curve of administered HBIG12). 
In addition， HBsAg was first detected at the age 
of 5 months in the 2 carrier infants， while al 
carrier infants became HBsAg-positive within 4 
HBIG might 1. months neonatally in the contro
delay the infantile deve10pment of carrier state. 
seven of，)1B1.As demonstrated by Yano et a 
32 infants (21. 9 弘) who received only百 BIG 
acquired persistent HBsAb within 12 months after 
birth. This spontaneous immunIz ation rate is not 
significantly higher than that of the control (19.2 
%). Supposedly passive immunization with HBIG 
might not enhance the postnatal spontaneous 
acquisition of HBs Ab. 
The active immunization rate with HB vaccine 
has reached 46.7% of the infants at present and 
may be expected to increase further in the near 
future， indicating promising practical utility of 
HB vaccine in preventing yertical and/or hori-
zontal infantile infection of HBV. 
As to infantile immune responses to HB vaccine， 
there were no signi長 cantdifferences between the 
two groups， i. e. group A， B and D where 
the五 rstvaccination was carried out beyond 12 
months， and group C， at the age of 4 months. 
Accordingly， HB vaccination could be started at 
the age of 4 months at latest as successfully as， 
beyond the age of 12 months. Further clinical 
trials in HB vaccination might enable us to start 
the五 rstHB vaccination much earlier， as re-
presented by group E. Early infantile HB vacci-
nation carries certain advantages such as saving 
on HBIG and al accompanied e茸 ortsand trou・ 
bles of medical sta笠 s， patients and their fami-
1. as wel，lies 
In summary， this study demonstrates and su-
ggests: 
l)Approximately 76% of the volunteers deve-
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loped persistent HBsAb-positive response without 
any side e百 ectby the長 rstand second booster va・ 
ccination. The third booster vaccination revealed 
prominent immunIzing e査 ect， attaining 96% in 
rate of HBsAb occurrence. 
2)Of the 32 infants， two (6.3%) developed 
carrier state，五 fteen(46.9%) acquired persistent 
HBsAb and the remaining 15 stayed undetermined， 
suggesting promising e伍 cacyof combined passive 
and active immunIzation therapy. 
3)The two carrier infants received豆 BIGev-
ery 4 months， while no infants who received 
ヨ BIGevery 3 months developed carrier state， 
indicating proper interval of HBIG administration. 
4)As to infantile immune responses to HB 
vaccine， there were no signi五 cantdi宣 erencesbe-
tween the two groups， 14 infants vaccinated be-
yond 12 months and 13 ones done at the age 
of 4 months. This五 ndingsuggests the possibility 
of early successful HB vaccination for preventing 
HBV vertical transmission. 
5)No serious side effects were found. 
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